At #EAU25, Dr.Nikhil Mayor (Imperial College London) presented results from the NeuroSAFE PROOF trial (NCT03317990)—the first randomized, controlled, single-blinded study comparing NeuroSAFE-guided versus standard robot-assisted radical prostatectomy (RARP) in localized prostate cancer.
NeuroSAFE, which enables real-time intraoperative margin assessment, led to significantly improved erectile function (EF) recovery at 12 months (mean IIEF-5: 12.7 vs 9.7; p < 0.001) and better urinary continence at 3 months, with no compromise in oncological safety. Patients not initially eligible for bilateral nerve-sparing benefited most.
These findings support NeuroSAFE as a transformative tool for optimizing functional outcomes in prostate cancer surgery.
Special thanks to Dr. Nikhil Mayor for presenting this important work, and to the entire NeuroSAFE PROOF trial team including investigators from Imperial College London, University College London, Guy’s and St Thomas’ NHS Foundation Trust, and the University of Leeds for their commitment to advancing patient-centered surgical care.
For more information, check the whole presentation: https://lnkd.in/di24RGqt
